Payment overview · 2025
General Payments
$285.98
9 reported records · 5 companies
Healthcare provider profile · identity verified
Pravinchandra K. Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUSQUEHANNA, PA · NPI 1992749477
Verified facts
What the public records show
CMS Open Payments records show Pravinchandra K. Patel, MD received $285.98 in general payments during 2025 across 9 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 43.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.00 | 43.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.68 | 36.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.91 | 8.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.02 | 6.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.37 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $285.98 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.97 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.93 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.93 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 357 | 108 |
| Lisinopril | Lisinopril | 346 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 322 | 90 |
| Furosemide | Furosemide | 286 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 276 | 54 |
| Losartan Potassium | Losartan Potassium | 221 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 43 |
| Metformin Hcl | Metformin Hcl | 209 | 54 |
| Potassium Chloride | Potassium Chloride | 202 | 38 |
| Famotidine | Famotidine | 197 | 56 |
| Eliquis | Apixaban | 194 | 36 |
| Alprazolam | Alprazolam | 193 | 43 |
| Simvastatin | Simvastatin | 192 | 51 |
| Omeprazole | Omeprazole | 185 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 35 |
| Sertraline Hcl | Sertraline Hcl | 148 | 32 |
| Gabapentin | Gabapentin | 147 | 32 |
| Meloxicam | Meloxicam | 139 | 46 |
| Clonidine Hcl | Clonidine Hcl | 131 | 32 |
| Nifedipine Er | Nifedipine | 127 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 107 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 105 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 33 |
| Tramadol Hcl | Tramadol Hcl | 98 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 27 |
| Glimepiride | Glimepiride | 87 | 25 |
| Allopurinol | Allopurinol | 85 | 21 |
| Montelukast Sodium | Montelukast Sodium | 81 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 18 |
| Ozempic | Semaglutide | 71 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 70 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 20 |
| Risperidone | Risperidone | 69 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 16 |
| Prednisone | Prednisone | 61 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | suppressed |
| Jardiance | Empagliflozin | 58 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Atenolol | Atenolol | 55 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 49 | suppressed |
| Carvedilol | Carvedilol | 47 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 28 |
| Trazodone Hcl | Trazodone Hcl | 47 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Enulose | Lactulose | 44 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 11 |
| Tradjenta | Linagliptin | 42 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 40 | 40 |
| Cephalexin | Cephalexin | 40 | 31 |
| Torsemide | Torsemide | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 33 |
| Cefuroxime | Cefuroxime Axetil | 38 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 12 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Dutasteride | Dutasteride | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 31 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Invokana | Canagliflozin | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | 13 |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 11 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Dapsone | Dapsone | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Fentanyl | Fentanyl | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Exelon | Rivastigmine | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $285.98 · 9 records | Otsuka America Pharmaceutical, Inc. | FARXIGA, Ozempic, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, Wegovy, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error